Expert Commentary

New and promising GSM treatments, more clinical takeaways from NAMS 2018

Author and Disclosure Information

Dr. Richard-Davis served as the Scientific Program Chair of the 2018 North American Menopause Society (NAMS) Meeting. In this audiocast she highlights several clinical takeaways from the meeting, including:

  • new treatments for uterine fibroids
  • the telomere’s role in helping women live longer lives, and protective (estrogen) and adverse (stress, obesity) factors affecting telomere length that patients can address through a healthy lifestyle
  • the legal risks of not screening for hereditary cancer
  • obesity prevention, treatment, and long-term lifestyle changes during menopause
  • new and on-the-horizon therapies for GSM
  • much more.


 

Learn more about NAMS: http://www.menopause.org/home

Recommended Reading

A combination hormone capsule for vasomotor symptoms
MDedge ObGyn
Postmenopausal estrogen use down since 2006
MDedge ObGyn
Migraine and menopause: Longitudinal study shows what to expect
MDedge ObGyn
What works best for genitourinary syndrome of menopause: vaginal estrogen, vaginal laser, or combined laser and estrogen therapy?
MDedge ObGyn
Guidelines released for perimenopausal depression
MDedge ObGyn
Zoledronate reduces fracture risk in elderly women with osteopenia
MDedge ObGyn
No falls, fractures, or bone density benefits from vitamin D supplements
MDedge ObGyn
For dyspareunia, intravaginal prasterone may work best soon after menopause
MDedge ObGyn
With more mindfulness, menopausal symptoms wane
MDedge ObGyn
No signal for CV, breast effects with bioidentical vaginal estrogen for dyspareunia
MDedge ObGyn